Astrocytoma, IDH-mutant, grade 3

Clinical trials for Astrocytoma, IDH-mutant, grade 3 explained in plain language.

Never miss a new study

Get alerted when new Astrocytoma, IDH-mutant, grade 3 trials appear

Sign up with your email to follow new studies for Astrocytoma, IDH-mutant, grade 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 4 Not yet recruiting 1 Not yet finished but already full! 1 Completed 1

New hope for brain tumor patients when standard drug fails

Disease control Not yet recruiting

This study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…

Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3

Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control

Last updated Aug 30, 2026 00:00 UTC

Astrocytoma, IDH-mutant, grade 3

Get alerted when new Astrocytoma, IDH-mutant, grade 3 trials appear

New hope for brain tumor patients when standard drug fails